Open AccessEvaluation of first-line therapies for the treatment of candidemia in ICU patients: A propensity score analysis
Author(s) -
AnneLise Bienvenu,
Pierre Pradat,
Claude Guérin,
Frédéric Aubrun,
Jean-Luc Fellahi,
Arnaud Friggeri,
Céline Guichon,
Romain Hernu,
Jean Ménotti,
Céline Monard,
S. Paulus,
Thomas Rimmelé,
Vincent Piriou,
Christian Chidiac,
Laurent Argaud,
Gilles Leboucher
Publication year - 2020
Publication title -
international journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.278
H-Index - 89
eISSN - 1878-3511
pISSN - 1201-9712
DOI - 10.1016/j.ijid.2020.01.037
Subject(s) - caspofungin , echinocandin , medicine , voriconazole , fluconazole , anidulafungin , intensive care unit , propensity score matching , context (archaeology) , intensive care medicine , retrospective cohort study , univariate analysis , multivariate analysis , antifungal , biology , paleontology , dermatology
Candidemia is a major cause of mortality in the intensive care unit (ICU). According to the Infectious Diseases Society of America (IDSA), an echinocandin is recommended as initial therapy and fluconazole as an alternative. In a context of echinocandin resistance development, the question arising is whether azoles are a suitable alternative to echinocandins for the treatment of candidemia in critically ill patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom